|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ricarte-Filho JC, Ryder M, Chitale DA, et
al: Mutational profile of advanced primary and metastatic
radioactive iodine-refractory thyroid cancers reveals distinct
pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res.
69:4885–4893. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xing M: Genetic alterations in the
phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
Thyroid. 20:697–706. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wilhelm SM, Carter C, Tang L, et al: BAY
43-9006 exhibits broad spectrum oral antitumor activity and targets
the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in
tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gril B, Palmieri D, Qian Y, et al:
Pazopanib reveals a role for tumor cell B-Raf in the prevention of
HER2+ breast cancer brain metastasis. Clin Cancer Res.
17:142–153. 2010. View Article : Google Scholar
|
|
6
|
Poulikakos PI, Zhang C, Bollag G, Shokat
KM and Rosen N: RAF inhibitors transactivate RAF dimers and ERK
signalling in cells with wild-type BRAF. Nature. 464:427–430. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hatzivassiliou G, Song K, Yen I, et al:
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and
enhance growth. Nature. 464:431–435. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Heidorn SJ, Milagre C, Whittaker S, et al:
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor
progression through CRAF. Cell. 140:209–221. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lito P, Pratilas CA, Joseph EW, et al:
Relief of profound feedback inhibition of mitogenic signaling by
RAF inhibitors attenuates their activity in BRAFV600E melanomas.
Cancer Cell. 22:668–682. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arnault JP, Mateus C, Escudier B, et al:
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway
activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin
Cancer Res. 18:263–272. 2012. View Article : Google Scholar
|
|
11
|
Montero-Conde C, Ruiz-Llorente S,
Dominguez JM, et al: Relief of feedback inhibition of HER3
transcription by RAF and MEK inhibitors attenuates their antitumor
effects in BRAF-mutant thyroid carcinomas. Cancer Discov.
3:520–533. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kumar R, Knick VB, Rudolph SK, et al:
Pharmacokinetic-pharmacodynamic correlation from mouse to human
with pazopanib, a multikinase angiogenesis inhibitor with potent
antitumor and antiangiogenic activity. Mol Cancer Ther.
6:2012–2021. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sternberg CN, Davis ID, Mardiak J, et al:
Pazopanib in locally advanced or metastatic renal cell carcinoma:
results of a randomized phase III trial. J Clin Oncol.
28:1061–1068. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van der Graaf WT, Blay JY, Chawla SP, et
al EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group:
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a
randomised, double-blind, placebo-controlled phase 3 trial. Lancet.
379:1879–1886. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bible KC, Suman VJ, Molina JR, et al
Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer
Center; Mayo Phase 2 Consortium: Efficacy of pazopanib in
progressive, radioiodine-refractory, metastatic differentiated
thyroid cancers: results of a phase 2 consortium study. Lancet
Oncol. 11:962–972. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Flaherty KT, Robert C, Hersey P, et al
METRIC Study Group: Improved survival with MEK inhibition in
BRAF-mutated melanoma. N Engl J Med. 367:107–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hurwitz HI, Dowlati A, Saini S, et al:
Phase I trial of pazopanib in patients with advanced cancer. Clin
Cancer Res. 15:4220–4227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gilmartin AG, Bleam MR, Groy A, et al:
GSK1120212 (JTP-74057) is an inhibitor of MEK activity and
activation with favorable pharmacokinetic properties for sustained
in vivo pathway inhibition. Clin Cancer Res. 17:989–1000. 2012.
View Article : Google Scholar
|
|
20
|
Bible KC1, Suman VJ, Menefee ME, et al
Mayo Phase 2 Consortium; Mayo Clinic Endocrine Malignances Disease
Oriented Group: A multiinstitutional phase 2 trial of pazopanib
monotherapy in advanced anaplastic thyroid cancer. J Clin
Endocrinol Metab. 97:3179–3184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Flaherty KT, Infante JR, Daud A, et al:
Combined BRAF and MEK inhibition in melanoma with BRAF V600
mutations. N Engl J Med. 367:1694–1703. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim KB, Kefford R, Pavlick AC, et al:
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients
with metastatic BRAF-mutant cutaneous melanoma previously treated
with or without a BRAF inhibitor. J Clin Oncol. 31:482–489. 2013.
View Article : Google Scholar
|
|
23
|
Ball DW, Jin N, Rosen DM, Dackiw A,
Sidransky D, Xing M and Nelkin BD: Selective growth inhibition in
BRAF mutant thyroid cancer by the mitogen-activated protein kinase
kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab.
92:4712–4718. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Leboeuf R, Baumgartner JE, Benezra M, et
al: BRAFV600E mutation is associated with preferential
sensitivity to mitogen-activated protein kinase kinase inhibition
in thyroid cancer cell lines. J Clin Endocrinol Metab.
93:2194–2201. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ho AL, Grewal RK, Leboeuf R, et al:
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
N Engl J Med. 368:623–632. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ascierto PA, Schadendorf D, Berking C, et
al: MEK162 for patients with advanced melanoma harbouring NRAS or
Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Lancet Oncol. 14:249–256. 2013. View Article : Google Scholar : PubMed/NCBI
|
